Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials

International Journal of Cardiology

Volumn 219, Issue , 2016, Pages 293-300

  Su, Na ^a   Li, Yun ^a,b   Xu, Ting ^a   Li, Ling ^a   Kwong, Joey Sum Wing ^a   Du, Heyue ^a   Ren, Kaiun ^a   Li, Qianrui ^b   Li, Jianshu ^c   Sun, Xin ^a   Li, Sheyu ^a   Tian, Haoming ^a  

^a SICHUAN UNIVERSITY   (China)

^b Department of Pathology The Third People's Hospital of Chengdu   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Body mass index; Exenatide; Meta analysis; Obesity; Overweight

Indexed keywords

CHOLESTEROL; EXENDIN 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

ABDOMINAL DISTENSION; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HYPOGLYCEMIA; META ANALYSIS; NAUSEA; OBESITY; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THYROID TUMOR; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; AGONISTS; DIABETES MELLITUS; DRUG EFFECTS; METABOLISM; OVERWEIGHT; PHYSIOLOGY; PROCEDURES;

BODY WEIGHT; DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; OVERWEIGHT; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOMS; WEIGHT LOSS;

EID: 84975893286     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.06.028     Document Type: Article

References (34)

1. World Health Organization Obesity http://www.who.int/topics/obesity/en/ (accessed 24 August 2015)
2. World Health Organization Obesity and overweight http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed 24 August 2015)
3. World Health Organization Obesity http://www.who.int/gho/ncd/risk-factors/obesity-text/en/ (accessed 24 August 2015)
4. C.M. Apovian, L.J. Aronne, D.H. Bessesen, M.E. McDonnell, M.H. Murad, U. Pagotto, and et al. Pharmacological management of obesity: an endocrine society clinical practice guideline J. Clin. Endocrinol. Metab. 100 2015 342 362
5. J.B. Buse, D.C. Klonoff, L.L. Nielsen, X. Guan, C.L. Bowlus, J.H. Holcombe, and et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analyses of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Clin. Ther. 29 2007 139 153
6. D.M. Kendall, M.C. Riddle, J. Rosenstock, D. Zhuang, D.D. Kim, M.S. Fineman, and et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 28 2005 1083 1091
7. E.W. Iepsen, J. Lundgren, C. Dirksen, J.E. Jensen, O. Pedersen, T. Hansen, and et al. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss Int. J. Obes. 39 2015 834 841
8. J.P.T. Higgins, S. Green Collaboration, T.C. Cochrane handbook for systematic reviews of interventions http://handbook.cochrane.org (accessed 24 August 2015)
9. A.S. Kelly, K.D. Rudser, B.M. Nathan, C.K. Fox, A.M. Metzig, B.J. Coombes, and et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial JAMA Pediatr. 167 2013 355 360
10. A.S. Kelly, R.M. Bergenstal, J.M. Gonzalez-Campoy, H. Katz, and A.J. Bank Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial Cardiovasc. Diabetol. 11 2012 64
11. A.S. Kelly, A.M. Metzig, K.D. Rudser, A.K. Fitch, C.K. Fox, B.M. Nathan, and et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study Obesity (Silver Spring) 20 2012 364 370
12. J. Dushay, C. Gao, G.S. Gopalakrishnan, M. Crawley, E.K. Mitten, E. Wilker, and et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes Diabetes Care 35 2012 4 11
13. J. Rosenstock, L.J. Klaff, S. Schwartz, J. Northrup, J.H. Holcombe, K. Wilhelm, and et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes Diabetes Care 33 2010 1173 1175
14. K. Elkind-Hirsch, O. Marrioneaux, M. Bhushan, D. Vernor, and R. Bhushan Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome J. Clin. Endocrinol. Metab. 93 2008 2670 2678
15. F. Zhang, Y. Tong, N. Su, Y. Li, L. Tang, L. Huang, and et al. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: a systematic review and meta-analyses of randomized controlled trials J. Diabetes 7 2015 329 339
16. S. Nikfar, M. Abdollahi, and P. Salari The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analyses of randomized clinical trials J. Pharm. Pharm. Sci. 15 2012 1 30
17. M. Monami, I. Dicembrini, N. Marchionni, C.M. Rotella, and E. Mannucci Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis Exp. Diabetes Res. 1-8 2012
18. T. Vilsbøll, M. Christensen, A.E. Junker, F.K. Knop, and L.L. Gluud Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ 10 2012 d7771
19. A. Lund, F.K. Knop, and T. Vilsbøll Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities Eur. J. Intern. Med. 25 2014 407 414
20. A. Astrup, S. Rössner, L. Van Gaal, A. Rissanen, L. Niskanen, M. Al Hakim, and et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 2009 1606 1616
21. X. Pi-Sunyer, A. Astrup, K. Fujioka, F. Greenway, A. Halpern, M. Krempf, and et al. Randomized, controlled trial of 3.0 mg of liraglutide in weight management N. Engl. J. Med. 373 2015 11 22
22. S. Brunton, and J.A. Davidson Exenatide once weekly: a review of pharmacology and treatment considerations in type 2 diabetes Clin. Ther. 38 2016 582 594
23. X.H. Guo The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide Curr. Med. Res. Opin. 32 2016 61 76
24. U.S. Food and Drug Administration, Drug @ FDA Metformin hydrochloride tablets http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/020357s031,021202s016lbl.pdf (accessed 10 May 2016)
25. L. Mou, J. Jiang, Z. Lin, J. Su, B. Sun, Y. Zhuang, and et al. The safety of exenatide administered in non-diabetic obese population Clin. J. Integr. Tradit. Chin. West. Med. 14 2014 3 5 (Chinese)
26. D.P. Bradley, R. Kulstad, N. Racine, Y. Shenker, M. Meredith, and D.A. Schoeller Alterations in energy balance following exenatide administration Appl. Physiol. Nutr. Metab. 37 2012 893 899
27. O.G. Kolterman, D.D. Kim, L. Shen, J.A. Ruggles, L.L. Nielsen, M.S. Fineman, and et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus Am. J. Health Syst. Pharm. 62 2005 173 181
28. H. Linnebjerg, P.A. Kothare, M. Seger, A.M. Wolka, and M.I. Mitchell Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with type 2 diabetes Int. J. Clin. Pharmacol. Ther. 49 2011 99 108
29. C.H. Wysham In reply-long-term efficacy and safety of exenatide treatment Mayo Clin. Proc. Ther. 90 2015 1304 1305
30. U.S. Food and Drug Administration, Drug @ FDA BYETTA (exenatide) injection http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/021773s040lbl.pdf (accessed 14 February 2015)
31. American Diabetes Association Approaches to glycemic treatment Diabetes Care 39 2016 S52 S59
32. L. Li, J. Shen, M.M. Bala, J.W. Busse, S. Ebrahim, P.O. Vandvik, and et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analyses of randomised and non-randomised studies BMJ 348 2014 g2366
33. K.B. Filion, L. Azoulay, R.W. Platt, M. Dahl, C.R. Dormuth, K.K. Clemens, and et al. A multicenter observational study of incretin-based drugs and heart failure N. Engl. J. Med. 374 2016 1145 1154
34. L. Li, S. Li, J. Liu, K. Deng, J.W. Busse, P.O. Vandvik, and et al. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies BMC Cardiovasc. Disord. 11 2016 91